menu
    • menu
    [{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Eflapegrastim","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Spectrum Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Unicycive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Lanthanum Dioxycarbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"GCSF","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Spectrum Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Poziotinib","moa":"EGFR","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim-xnst","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Spectrum Pharmaceuticals","amount2":0.76000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.76000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Spectrum Pharmaceuticals \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim-xnst","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Spectrum Pharmaceuticals \/ Assertio Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Spectrum Pharmaceuticals

    Menu

    Spectrum Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflapegrastim-xnst

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Assertio Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction

                            Details : Through the acquisition, Assertio will expand its product portfolio by including Rolvedon (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation for the treatment of febrile neutropenia.

                            Brand Name : Rolvedon

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 31, 2023

                            Lead Product(s) : Eflapegrastim-xnst

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Assertio Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflapegrastim-xnst

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Assertio Therapeutics

                            Deal Size : $757.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction

                            Details : Through the acquisition, Assertio will expand its product portfolio by including Rolvedon (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation for the treatment of febrile neutropenia.

                            Brand Name : Rolvedon

                            Molecule Type : Large molecule

                            Upfront Cash : $291.0 million

                            April 25, 2023

                            Lead Product(s) : Eflapegrastim-xnst

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Assertio Therapeutics

                            Deal Size : $757.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflapegrastim

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spectrum Pharmaceuticals Provides Update on Rolvedon™ (eflapegrastim-xnst) Injection and Announces Unaudited...

                            Details : ROLVEDON™ (eflapegrastim-xnst) injection is a long-acting G-CSF which decreases the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

                            Brand Name : Rolvedon

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 31, 2023

                            Lead Product(s) : Eflapegrastim

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Poziotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meetin...

                            Details : HM781-36B (poziotinib) is a novel, oral EGFR TKI that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4, which, in turn, leads to the inhibition of the proliferation of tumor cells that overexpress these receptors.

                            Brand Name : HM781-36B

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 22, 2022

                            Lead Product(s) : Poziotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Poziotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P7...

                            Details : HM781-36B (poziotinib) is a novel, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4.

                            Brand Name : HM781-36B

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 10, 2022

                            Lead Product(s) : Poziotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflapegrastim

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection

                            Details : ROLVEDON™ (eflapegrastim-xnst) injection is a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation,is indicated to decrease the incidence of infection, as manifested by febrile neutropenia.

                            Brand Name : Rolvedon

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 09, 2022

                            Lead Product(s) : Eflapegrastim

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Poziotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2...

                            Details : HM781-36B (poziotinib) is a novel, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4.

                            Brand Name : HM781-36B

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 05, 2022

                            Lead Product(s) : Poziotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Poziotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ct...

                            Details : HM781-36B (Poziotinib), novel, oral epidermal growth factor receptor tyrosine kinase inhibitor that inhibits tyrosine kinase activity of EGFR, HER2 and HER4. Importantly this, in turn, leads to inhibition of proliferation of tumor cells that overexpress ...

                            Brand Name : HM781-36B

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 26, 2022

                            Lead Product(s) : Poziotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Poziotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual Meeting

                            Details : In pre-clinical models of cancer, poziotinib, an investigational, orally administered, irreversible tyrosine kinase inhibitor was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to can...

                            Brand Name : HM781-36B

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 04, 2022

                            Lead Product(s) : Poziotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Spectrum Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Poziotinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spectrum Pharmaceuticals Presents Positive Data for Poziotinib in First-line NSCLC Patients with HER2 Exon 20 ...

                            Details : ZENITH 20 study demonstrated positive results for Poziotinib, met its primary endpoint as the observed lower bound of 30% exceeded the pre-specified lower bound of 20%, showed a confirmed objective response rate of 41% in patients with non-small lung can...

                            Brand Name : HM781-36B

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 07, 2022

                            Lead Product(s) : Poziotinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth